The following is a summary of “An Updated Review of Immune Checkpoint Inhibitors in Cutaneous Oncology: Beyond Melanoma,” ...

Barclays (LON:BARC) reaffirmed its positive stance on Replimune Group (NASDAQ:REPL), maintaining an Overweight rating and a $17.00 price target, representing significant upside from the current price ...

The biologics license application for RP1 (vusolimogene oderparepvec) plus nivolumab in advanced melanoma was accepted by the ...

Shares of Replimune Group, Inc. (NASDAQ: NASDAQ: REPL) surged 17% following the announcement that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for ...

Scientists in China have developed a modified virus that causes cancer cells to make sugars normally found in pigs, causing ...

Molecular oncology is revolutionizing cancer care by using genetic profiling to tailor personalized treatments, improving ...

Replimune Group Inc (NASDAQ: NASDAQ:REPL), a biotech firm focused on oncolytic immunotherapies, announced today that its Biologics License Application (BLA) for RP1 in combination with nivolumab has ...

PDUFA action date of July 22, 2025, with priority reviewWOBURN, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the ...

Moles appear commonly on human skin, yet their presence demands attention and regular monitoring. While most remain harmless, ...

Traditionally carrying a dire prognosis, the treatment paradigm for multiple myeloma is changing, with CAR T therapies, ...

A fusion protein therapy may be an effective treatment option for cutaneous T-cell lymphomas, according to a multicenter ...

2024 was a year unlike any other for the British royal family, as Fergie, King Charles and Kate Middleton all announced that ...